Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease

Christoph J. Griessenauer, MD, Jeffrey D. Lebensburger, DO, Michelle H. Chua, BS, Winfield S. Fisher III, MD, Lee Hilliard, MD, Christina J. Bemrich-Stolz, MD, MSPH, Thomas H. Howard, MD, and James M. Johnston, MD

Departments of Neurosurgery and Pediatric Hematology Oncology, University of Alabama at Birmingham, Alabama; and Harvard Medical School, Boston, Massachusetts

OBJECT Pediatric patients with sickle cell disease (SCD) and moyamoya syndrome (MMS) are at significant risk for cerebrovascular accidents despite chronic transfusion therapy. Encephaloduroarteriosynangiosis (EDAS) and encephalomyoarteriosynangiosis (EMAS) are additional therapeutic options for these patients. To date, the incidence of complications after and efficacy of EDAS and EMAS in stroke prevention in this population have been described in several institutional case series reports, but no randomized prospective trials have been reported.

METHODS The authors retrospectively reviewed the cases of all pediatric patients at the University of Alabama at Birmingham with a history of homozygous hemoglobin S (HbS) and sickle cell/β-thalassemia (SB0 thalassemia) and on chronic transfusion therapy, including 14 patients with MMS who underwent EDAS or EMAS.

RESULTS Sixty-two patients with SCD and on chronic transfusion therapy were identified. After exclusion of patients on chronic transfusion therapy for indications other than stroke prevention, 48 patients (77.4%) remained. Of those patients, 14 (29.1%) underwent EDAS or EMAS. Nine (18.8%) and 25 (52.1%) patients were on chronic transfusion therapy for primary or secondary stroke prevention, respectively, but did not undergo EDAS or EMAS. The 14 patients with SCD and radiological evidence of MMS and on chronic transfusion therapy for primary or secondary stroke prevention underwent 21 EDAS or EMAS procedures for progressive vascular disease (92.9% of patients), stroke (71.4%), and/or seizure (7.1%). The mean (± SD) time from initiation of chronic transfusion therapy to EDAS or EMAS was 76.8 ± 58.8 months. Complications included 1 perioperative stroke, 1 symptomatic subdural hygroma, 1 postoperative seizure, and 1 case of intraoperative cerebral edema that required subsequent cranioplasty. Before EDAS or EMAS, the stroke rate was calculated to be 1 stroke per 7.8 patient-years. One additional stroke occurred during the follow-up period (mean follow-up time 33.7 ± 19.6 months), resulting in a post-EDAS/EMAS stroke rate of 1 stroke per 39.3 patient-years, a 5-fold reduction compared with that in the pre-EDAS/EMAS period. The patients’ mean pre-EDAS/EMAS HbS level of 29.5% ± 6.4% was comparable to the mean post-EDAS/EMAS HbS level of 25.5% ± 6.1% (p = 0.104).

CONCLUSIONS The results of this retrospective case series in a large cohort of pediatric patients with SCD and MMS suggest that EDAS/EMAS provides a stroke-prevention benefit with an acceptably low morbidity rate. Given the combined experience with EDAS and EMAS for this indication at this and other institutions, a prospective clinical trial to assess their efficacy compared with that of chronic transfusion therapy alone is warranted.


KEY WORDS moyamoya syndrome; sickle cell disease; vascular disorders
Strokes occur in approximately 10% of patients with sickle cell disease (SCD) before the age of 20 years. Strokes in patients with SCD account for significant morbidity and death in this patient population and are mainly attributed to microvascular and macrovascular arteriopathies. Microvascular arteriopathy may be related to sickle cell adhesion, subsequent stasis, and vascular occlusion at the level of the arteriole, capillaries, and postcapillary venule and accounts for approximately 25% of strokes, particularly in the susceptible deep white matter. Macrovascular arteriopathy is postulated to be responsible for approximately 75% of strokes and affects the more proximal cerebral circulation, where higher flow results in substantial shear stress on the walls of the arteries and turbulence at sites of bifurcation. Recurrent adhesion and release of sickle cells leads to endothelial injury followed by intimal hyperplasia and luminal stenosis. Injured arterial walls then promote thrombus formation and embolization. The progression from stenosis to occlusion of the supraclinoid internal cerebral and proximal anterior and middle cerebral arteries prompts the development of a collateral network of fragile small-caliber arteries arising from the lenticulostriate arteries that resembles a moyamoya pattern on arteriography. This so-called moyamoya syndrome (MMS) is present in 30% to 43% of patients with SCD and history of stroke.

Chronic transfusion therapy is the mainstay for primary stroke prevention in patients with evidence of cerebrovascular compromise based on transcranial Doppler (TCD) criteria and for secondary stroke prevention in patients with a history of stroke. This approach, however, does not protect all patients, especially those with progressive cerebrovascular disease, and it is associated with complications such as iron overload and increased risk for stroke with noncompliance or discontinuation of therapy. Surgical revascularization procedures, including direct and indirect bypass procedures, have been proposed to increase blood delivery to the ischemic brain. Of the indirect bypass procedures, encephaloduroarteriosynangiosis (EDAS) and encephalomyoarteriosynangiosis (EMAS) with pial synangiosis are the most commonly used, and recurrent adhesion and hematological data were assessed. Hemoglobin (Hb) and percentage HbS levels were obtained 1–3 days before every scheduled transfusion. For the patients receiving chronic transfusion therapy who did not undergo EDAS/EMAS, Hb and HbS levels were recorded from the date on which chronic transfusion therapy was initiated to the last follow-up visit. For the patients who underwent EDAS or EMAS, Hb and HbS levels were recorded from the time of the first abnormal MRI result to the last follow-up visit. Hb and HbS levels are expressed as the mean and SD of all Hb and HbS levels recorded over the time on chronic transfusion therapy versus the pre- and post-EDAS/EMAS periods in patients who did not and did undergo EDAS/EMAS, respectively.

**Methods**

After approval from the University of Alabama at Birmingham institutional review board, the case of each pediatric patient with SCD (homozygous hemoglobin S [HbS] and sickle cell/β-thalassemia [SB0 thalassemia]) and on chronic transfusion therapy between 2007 and 2014 at the University of Alabama at Birmingham and Children’s of Alabama was reviewed retrospectively. A stroke was defined as the new onset of a neurological deficit with correlated ischemic findings on imaging, whereas silent ischemic events were defined as ischemic imaging findings that remained clinically silent. Per the institutional protocol for management of stroke prevention in patients with SCD, a patient is started on chronic transfusion therapy for primary stroke prevention if a time-averaged mean blood flow velocity of ≥ 200 cm/sec in the terminal internal carotid artery (ICA) or middle cerebral artery (MCA) is detected with TCD screening. Any patient who has had a stroke or a silent ischemic event receives chronic transfusion therapy (or hydroxyurea) for secondary stroke prevention (Fig. 1). The study included patients with MMS who underwent EDAS or EMAS. The diagnosis of MMS was based on cerebrovascular imaging (MR angiography [MRA], CT angiography, and/or digital subtraction angiography [DSA]) conducted at presentation in symptomatic patients. Patients with neurovascular symptoms (i.e., stroke, transient ischemic attack, or seizures) and patients with evidence of progressive vascular disease and ischemic changes as revealed by MRI/MRA were recommended for EDAS/EMAS. Before EDAS/EMAS, patients had scheduled MRI/MRA surveillance every 1 to 2 years. Per institutional preference, children with a history of stroke or a silent ischemic event were not treated with aspirin prophylaxis.

Demographic information and clinical, radiological, and hematological data were assessed. Hemoglobin (Hb) and percentage HbS levels were obtained 1–3 days before every scheduled transfusion. For the patients receiving chronic transfusion therapy who did not undergo EDAS/EMAS, Hb and HbS levels were recorded from the date on which chronic transfusion therapy was initiated to the last follow-up visit. For the patients who underwent EDAS or EMAS, Hb and HbS levels were recorded from the time of the first abnormal MRI result to the last follow-up visit. Hb and HbS levels are expressed as the mean and SD of all Hb and HbS levels recorded over the time on chronic transfusion therapy versus the pre- and post-EDAS/EMAS periods in patients who did not and did undergo EDAS/EMAS, respectively.

**Perioperative and Postoperative Management After EDAS or EMAS**

Since 2011, all children undergoing EDAS/EMAS were admitted to the hospital the day before surgery for intravenous hydration to mitigate the risk of perioperative stroke and anesthesia-related complications. Transfusion therapy was given the day before the procedure with a goal Hb level of < 30% and a posttransfusion Hb level of at least 10 g/dl. In addition, each child underwent preoperative baseline electroencephalography and then was monitored intraoperatively with a limited montage. Each patient was noted to have at least 1 transient episode of intraoperative electroencephalographic slowing or decreased amplitude. A more detailed analysis of intraoperative electroencephalographic changes and utility of this information will be the subject of a future article. Episodes of electroencephalographic slowing or decreased amplitude during surgery were treated with elevation of mean arterial pressure and neuroprotective doses of propofol. Patients 1–6 underwent EMAS and Patients 7–14 underwent EDAS with pial synangiosis according to a method previously published by Adelson and Scott. Dural inversion was added to standard pial synangiosis in some children when feasible. All patients undergoing bilateral EDAS had staged operations.
The children were maintained in the intensive care unit overnight with careful attention to hydration and pain control and then were transferred to the floor the following day on 1.5-times maintenance fluids. Preoperative and follow-up MRA and/or DSA were assessed for arterial stenosis, arterial occlusion, graft patency, and neovascularization.

Statistical Analysis

Statistical analysis was performed using R version 3.1.1 (http://www.r-project.org). Categorical variables were compared between groups by the Fisher exact test. Numerical variables were compared between groups by ANOVA. A p value of < 0.05 was considered statistically significant.

Pairwise comparison as a follow-up to ANOVA was performed for time and Hb and HbS levels on transfusion therapy using t-tests. A p value of < 0.00278 was considered statistically significant using the Bonferroni correction for 18 comparisons ($\alpha^* = \alpha/K = 0.05/18 = 0.00278$) (Table 1).

Results

A total of 62 patients with SCD and on chronic transfusion therapy were included. After exclusion of patients with an indication for chronic transfusion therapy other than stroke prevention, 48 patients (77.4%) remained. Of those patients, 14 (29.2%) underwent EDAS or EMAS. Nine (18.8%) and 25 (52.1%) patients were on chronic transfusion therapy for primary or secondary stroke prevention, respectively, but did not undergo EDAS or EMAS (Table 1).

Patients With SCD on Chronic Transfusion Therapy for Primary or Secondary Stroke Prevention

Thirty-four patients were on chronic transfusion therapy for primary or secondary stroke prevention but did not undergo EDAS or EMAS. The mean ages of those patients were 11.5 ± 4.9 and 14.1 ± 6.0 years, respectively, and did not differ from that of the patients who underwent EDAS or EMAS (p = 0.277). MMS was present in 22.2% and 24.0% of the patients, respectively, and was present significantly less frequently than in the patients who underwent EDAS or EMAS (p < 0.0001). Pairwise comparison for Hb levels between groups did not affirm the statistical significance detected with ANOVA. HbS levels in patients on chronic transfusion therapy for primary and secondary stroke prevention compared less favorably than that in patients who underwent EDAS or EMAS, as evidenced
by mean HbS levels of 42.4% ± 12% and 34.3% ± 10.8%, respectively (p < 0.0001). This result was reaffirmed by pairwise comparison, which revealed that patients on chronic transfusion therapy for both primary and secondary stroke prevention had significantly higher HbS levels than patients after EDAS or EMAS (p = 0.00176 and 0.00255, respectively).

Patients With SCD and on Chronic Transfusion Therapy After EDAS/EMAS

Preoperative Course

A total of 14 patients (5 male and 9 female) with a mean age of 15.3 ± 5.3 years at the time of surgery underwent EMAS or EDAS (Table 2). The most common indication for the initial cerebrovascular imaging was screening (50% of patients), and the second most common indication was stroke (28.6%). The mean time from initiation of chronic transfusion therapy to EDAS/EMAS was 76.8 ± 58.8 months. Progressive vascular disease (92.9%) and history of stroke (71.4%) were the most common indications for EDAS/EMAS. Ten strokes occurred in 78.1 patient-years (total number of years that patients were followed before EDAS/EMAS) before EDAS/EMAS, which resulted in a calculated stroke rate of 1 per 7.8 patient-years. All patients were on chronic transfusion therapy and had a mean Hb level of 9.4 ± 0.4 g/dl and a mean HbS level of 29.5% ± 6.4%.

Radiographic Features

Preoperative MRI and MRA for all the patients were available for review. Each of the 10 patients who had a stroke before EDAS had correlating ischemic changes shown in MRI. The 4 patients without a stroke before EDAS also had evidence of ischemic events on MRI. During the pre-EDAS/EMAS period, there were 10 ischemic events in 9 patients (64.3%) that remained clinically silent. For 7 patients who each had bilateral MMS, pre-EDAS/EMAS DSA studies were available and reviewed. The median Suzuki grade was 4 (range 3–5) (Table 2). Bilateral progressive vascular disease was present in 12 (85.7%) of the 14 patients. Ten (71.4%) of the 14 patients had bilateral ischemic changes, as revealed in MRI.

Surgical Technique

Information on the surgeries and outcomes is presented in Table 3. In Patients 1–6, the donor scalp artery, most commonly the posterior branch of the superficial temporal artery, was transposed with a small muscle cuff still attached (EMAS25). In the remainder of the patients, the technical aspects of EDAS were performed as previously described. Intraoperative cerebral edema that precluded replacement of the bone flap. In Patient 1, who suffered a stroke 2 weeks after surgery, MRI revealed new ischemic changes in the left frontoparietal region, and the child re-

| TABLE 1. All patients on transfusion therapy for stroke prevention, including those who underwent EDAS or EMAS |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Characteristic** | **All Patients** | **For Primary Stroke Prevention** | **For Secondary Stroke Prevention** | **Patients Who Underwent EDAS/EMAS** |
|                  | **(n = 48)**    | **(n = 9)**     | **(n = 25)**    | **Before EDAS/EMAS (n = 14)**           |
| **Demographics** |                 |                 |                 | **After EDAS/EMAS** | **p Value** |
| Age (mean ± SD) (yrs) | 14.0 ± 5.7 | 11.5 ± 4.9 | 14.1 ± 6.0 | 15.3 ± 5.3 | 0.277 |
| Sex (no. [%]) | | | | | 0.243 |
| Male | 20 (41.7) | 6 (66.7) | 9 (36.0) | 5 (35.7) | |
| Female | 28 (58.3) | 3 (33.3) | 16 (64.0) | 9 (64.3) | |
| Imaging results (no. [%]) | | | | | 0.0001 |
| Initiation of chronic transfusion therapy after TCD screening | 16 (33.3) | 9 (100) | 0 (0) | 7 (50) | |
| Presence of MMS | 22 (45.8) | 2 (22.2) | 6 (24.0) | 14 (100) | |
| Chronic transfusion therapy | | | | | <0.0001 |
| Time on transfusion therapy (mean ± SD) (mos) | 102.8 ± 62.4 | 85.8 ± 54.4 | 104.6 ± 67.7 | 76.8 ± 58.8 | 33.7 ± 19.6 | 0.00477 |
| Hb level on chronic transfusion therapy (mean ± SD) (g/dl) | 9.3 ± 0.8 | 9.1 ± 0.6 | 9.1 ± 0.9 | 9.4 ± 0.4 | 9.9 ± 0.7 | 0.00912 |
| HbS level on chronic transfusion therapy (mean ± SD) (%) | 33.9 ± 10.7 | 42.4 ± 12 | 34.3 ± 10.8 | 29.5 ± 6.4 | 25.5 ± 6.1 | <0.0001 |

Unauthenticated | Downloaded 04/28/22 01:44 PM UTC
TABLE 2. Information for patients who underwent EDAS/EMAS, including preoperative imaging findings and hematological data

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yrs), Sex</th>
<th>Indication for Initial Imaging</th>
<th>Initial Vascular Imaging Findings (occlusion/stenosis)</th>
<th>Pre-EDAS Vascular Imaging Findings (occlusion/stenosis)</th>
<th>Bilat Vascular Disease</th>
<th>No. of Pre-EDAS Silent Ischemic Events</th>
<th>No. of Pre-EDAS Ischemic Events on Imaging (stroke or silent event)</th>
<th>Bilat Ischemic Events on Imaging</th>
<th>Suzuki Grade on DSA</th>
<th>Preop Imaging Follow-Up (mos)</th>
<th>Preop Transfusion Therapy (all chronic) Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12, F</td>
<td>Screening</td>
<td>Bilat ICA, rt MCA</td>
<td>Bilat ICA, rt MCA</td>
<td>Yes</td>
<td>2</td>
<td>3</td>
<td>Yes</td>
<td>5</td>
<td>3</td>
<td>28.3 9.8 23.8</td>
</tr>
<tr>
<td>2</td>
<td>19, M</td>
<td>HA, NV</td>
<td>Normal</td>
<td>Bilat ICA, bilat MCA</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>158.7 9.0 38.4</td>
</tr>
<tr>
<td>3</td>
<td>21, F</td>
<td>Seizure</td>
<td>Bilat ICA, bilat ACA, lt MCA</td>
<td>Bilat ICA, bilat ACA, lt MCA</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>113.3 9.3 35.9</td>
</tr>
<tr>
<td>4</td>
<td>20, F</td>
<td>Stroke</td>
<td>Lt ICA, lt ACA, lt MCA</td>
<td>Bilat ICA, lt ACA, lt MCA</td>
<td>Yes</td>
<td>1</td>
<td>2</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>31.5 9.1 26.9</td>
</tr>
<tr>
<td>5</td>
<td>20, F</td>
<td>Screening</td>
<td>Bilat ICA, bilat ACA, bilat PCA</td>
<td>Bilat ICA, bilat ACA, bilat PCA, rt MCA</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>52.1 9.7 37.0</td>
</tr>
<tr>
<td>6</td>
<td>10, M</td>
<td>Seizure</td>
<td>Normal</td>
<td>Lt ICA, lt ACA, lt MCA, lt PCA</td>
<td>No</td>
<td>1</td>
<td>1</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>90.9 9.3 23.0</td>
</tr>
<tr>
<td>7</td>
<td>7, F</td>
<td>Stroke</td>
<td>Bilat ICA</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Yes</td>
<td>1</td>
<td>2</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>23.7 9.3 39.5</td>
</tr>
<tr>
<td>8</td>
<td>17, M</td>
<td>Screening</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Yes</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>18.8 9.9 25.8</td>
</tr>
<tr>
<td>9</td>
<td>5, F</td>
<td>Stroke</td>
<td>Lt ICA, lt ACA, lt MCA</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>9.0 21.0</td>
</tr>
<tr>
<td>10</td>
<td>19, M</td>
<td>Screening</td>
<td>Lt MCA</td>
<td>Lt ICA, bilat ACA, lt MCA</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>No</td>
<td>4</td>
<td>3</td>
<td>164.9 8.7 22.4</td>
</tr>
<tr>
<td>11</td>
<td>18, F</td>
<td>Screening</td>
<td>Normal</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Yes</td>
<td>1</td>
<td>2</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>122.9 8.9 34.0</td>
</tr>
<tr>
<td>12</td>
<td>14, F</td>
<td>Stroke</td>
<td>Bilat MCA</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Yes</td>
<td>1</td>
<td>2</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>50.1 10.0 25.3</td>
</tr>
<tr>
<td>13</td>
<td>20, F</td>
<td>Screening</td>
<td>Bilat ICA, lt ACA, lt MCA</td>
<td>Bilat ICA, lt ACA, lt MCA</td>
<td>Yes</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>119.7 9.9 30.5</td>
</tr>
<tr>
<td>14</td>
<td>13, M</td>
<td>Screening</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Bilat ICA, bilat ACA, bilat MCA</td>
<td>Yes</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
<td>0</td>
<td>1</td>
<td>18.8 9.8 29.6</td>
</tr>
</tbody>
</table>

ACA = anterior cerebral artery; HA = headache; NV = nausea and vomiting; PCA = posterior cerebral artery.
* Patients 7 and 9 were not on chronic transfusion therapy at the time of their initial stroke.
<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Indication</th>
<th>Procedure Type</th>
<th>Side</th>
<th>Postop Complications</th>
<th>Neurological Outcome</th>
<th>Follow-Up (mos)</th>
<th>Imaging Outcome</th>
<th>Follow-Up (mos)</th>
<th>Imaging Outcome</th>
<th>Postop Transfusion Therapy (all chronic) Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Bilat</td>
<td>Stroke 2 wks postop</td>
<td>Intact</td>
<td>49.8</td>
<td>Yes, bilat</td>
<td>49.5</td>
<td>Yes, bilat</td>
<td>10.3 14.6</td>
</tr>
<tr>
<td>2</td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Rt</td>
<td>None</td>
<td>Intact</td>
<td>42.1</td>
<td>Yes</td>
<td>44.4</td>
<td>Yes</td>
<td>11.0 33.1</td>
</tr>
<tr>
<td>3</td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Rt</td>
<td>None</td>
<td>Rt hemiparesis</td>
<td>50.1</td>
<td>Yes</td>
<td>50.6</td>
<td>Yes</td>
<td>9.7 29.7</td>
</tr>
<tr>
<td>4</td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Lt</td>
<td>None</td>
<td>Intact</td>
<td>51.0</td>
<td>Yes</td>
<td>43.0</td>
<td>Yes</td>
<td>9.1 25.1</td>
</tr>
<tr>
<td>5</td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Rt</td>
<td>None</td>
<td>Intact</td>
<td>74.4</td>
<td>Yes</td>
<td>63.2</td>
<td>Yes</td>
<td>10.1 22.7</td>
</tr>
<tr>
<td>6</td>
<td>Progressive vascular disease</td>
<td>EMAS</td>
<td>Lt</td>
<td>Postop subdural hygroma that required evacuation</td>
<td>Intact</td>
<td>37.7</td>
<td>Yes</td>
<td>11.2</td>
<td>Yes</td>
<td>9.7 15.0</td>
</tr>
<tr>
<td>7</td>
<td>Progressive vascular disease</td>
<td>EDAS, dural inversion</td>
<td>Lt</td>
<td>Cerebral edema that required delayed cranioplasty</td>
<td>Intact</td>
<td>21.6</td>
<td>Yes</td>
<td>12.2</td>
<td>Yes</td>
<td>9.5 35.2</td>
</tr>
<tr>
<td>8</td>
<td>Progressive vascular disease</td>
<td>EDAS, dural inversion</td>
<td>Lt</td>
<td>Cerebral edema that required delayed cranioplasty</td>
<td>Intact</td>
<td>4.9</td>
<td>Yes</td>
<td>15.1</td>
<td>Yes</td>
<td>9.7 25.7</td>
</tr>
<tr>
<td>11</td>
<td>Progressive vascular disease</td>
<td>EDAS, dural inversion</td>
<td>Lt</td>
<td>Cerebral edema that required delayed cranioplasty</td>
<td>Intact</td>
<td>12.4</td>
<td>Yes</td>
<td>10.9</td>
<td>Yes</td>
<td>21.5</td>
</tr>
<tr>
<td>12</td>
<td>Progressive vascular disease</td>
<td>EDAS, dural inversion</td>
<td>Rt</td>
<td>Cerebral edema that required delayed cranioplasty</td>
<td>Intact</td>
<td>4.4</td>
<td>Yes</td>
<td>10.1</td>
<td>Yes</td>
<td>20.4</td>
</tr>
</tbody>
</table>
turned to neurological baseline without permanent deficit. None of the other complications resulted in a transient or permanent neurological deficit. There were no deaths in the cohort.

Radiographic Outcome

All of the patients in the present series with radiological follow-up had a patent graft. Of the hemispheres on which surgery was performed, all but one (93.8%) showed radiological evidence of collateral formation at the last follow-up. No differences were noted between the patients who underwent dural inversion and those who did not. Radiological follow-up was obtained routinely via MRA to eliminate risks associated with DSA.

Clinical Outcome After Discharge

Other than in Patient 1, no additional strokes occurred during the clinical follow-up period (mean 33.7 ± 19.6 months). One stroke in 39.3 patient-years (total number of years patients were followed after EDAS/EMAS) after EDAS/EMAS resulted in a post-EDAS/EMAS stroke rate of 1 stroke per 39.3 patient-years, a 5-fold reduction in that of the pre-EDAS/EMAS period (1 stroke per 7.8 patient-years). Likewise, no additional ischemic events occurred. At the last follow-up, 10 (71.4%) of 14 patients were neurologically intact. Four patients (28.6%) suffered from persistent hemiparesis from their initial stroke (Table 3). The mean post-EDAS/EMAS HbS level was 25.5% ± 6.1%, not significantly different from that in the pre-EDAS/EMAS period ($p = 0.104$).

Discussion

In this study, we compared all pediatric patients with SCD and on chronic transfusion therapy for stroke prevention to patients who underwent EDAS or EMAS. Patients with SCD have an approximately 250-times-higher risk of stroke than the general childhood population. Chronic transfusion therapy is the mainstay treatment for primary and secondary neurovascular complications. Although chronic transfusion therapy prevents initial and recurrent stroke in the majority of patients, some patients on chronic transfusion therapy continue to experience strokes and develop progressive vascular disease. The progression of their vascular disease triggers the development of a fragile network of arteries that resembles MMD and is present in 30%–43% of patients with SCD and a history of stroke. In our study, 45.8% of the patients on chronic transfusion therapy had MMS. These patients in particular are at a high risk for strokes despite optimal medical therapy. This higher failure rate of chronic transfusion therapy in patients with SCD and MMS warrants the evaluation of supplemental alternative treatments. EDAS or EMAS with pial synangiosis, an indirect bypass procedure aimed at revascularizing the ischemic brain, was first performed in a patient with SCD in 1996 and has since been reported from small case series in other centers. A comparison of stroke rates before and after EDAS/EMAS revealed a significant reduction after the procedure. Results from our experience with indirect revascularization in 14 patients with SCD and MMS are consistent with those in these other series, with a similar complication rate and apparent improvement in overall stroke risk as measured by the number of strokes per patient-year. However, the majority of our patients did not undergo revascularization for years after their initial stroke and did not experience a second stroke during that waiting period. This relatively benign natural history, at least in terms of clinically diagnosed stroke, makes interpretation of the total stroke risk reduction (i.e., strokes per patient-year) after EDAS/EMAS for children with SCD much more problematic, especially after short a follow-up period.

Medical Management of MMS in Patients With SCD

The neurological sequelae of SCD include but are not limited to transient ischemic attack, stroke, hemorrhage, seizure, and decline in neurocognitive function and are associated with significant morbidity and death. Before TCD screening for stroke risk, approximately 10% of all children with SCD suffered a stroke, and recurrence rates ranged from 46% to 90% in patients who did not receive any secondary stroke-prevention therapy. Chronic transfusion therapy reduces stroke recurrence rates to approximately 10% to 20% and provides a 90% reduction in the rate of first stroke in patients at high risk as determined by increased blood-flow velocities on TCD. Patients at high risk have TCD velocities of the terminal ICA and MCA of ≥ 200 cm/sec. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) was a landmark prospective randomized stroke-prevention trial in patients with SCD at high risk for stroke; it found chronic transfusion therapy with a goal HbS level of ≤ 30% to be associated with a significant reduction in stroke risk, which led to early termination of the trial. However, chronic transfusion therapy for primary or secondary stroke prevention carries notable adverse effects, including iron overload and alloimmunization. In addition, chronic transfusion therapy is known to be less effective in patients who have developed MMS. Recent work showed that patients with SCD and MMS on chronic transfusion therapy with the identical HbS goal of 30% are twice as likely to incur recurrent strokes than are patients with SCD without MMS.

In our study, 18.8% of the patients were found to have a mean TCD velocity of ≥ 200 cm/sec and were placed on chronic transfusion therapy for primary stroke prevention. Fifty-two percent of the patients presented with a stroke or silent ischemic event and received chronic transfusion therapy for secondary stroke prevention. HbS levels in those patients were in the range of 42.4% ± 12% and 34.3% ± 10.8%, respectively, and compared less favorably to the levels of patients who underwent EDAS or EMAS and were more adequately managed on chronic transfusion therapy, as evidenced by mean HbS levels of 29.5% ± 6.4% and 25.5% ± 6.1% before and after EDAS/EMAS, respectively. Overall, the findings compare well to those of current chronic transfusion practice in patients with SCD, which were surveyed in a recent study that found an average pretransfusion HbS level of 35% ± 11%. When data from our patients with MMS after EDAS or EMAS were combined with those of patients from previous studies, 21 (47.7%) of 44 patients had suffered a stroke on chronic transfusion therapy. Two patients (Patients 7 and 9) in our...
series had their initial stroke while off transfusion therapy and were subsequently placed on it for secondary stroke prevention. It is unfortunate that previous studies did not include HbS data to demonstrate the adequacy of chronic transfusion therapy in their patients. Nevertheless, this number is comparable to the stroke rate of 58% in patients with MMS on chronic transfusion therapy reported previously.\textsuperscript{13} Whether chronic transfusion therapy slows the progression of vascular disease and prevents involvement of the contralateral hemisphere in patients with unilateral disease is uncertain.\textsuperscript{21} Contrary to an observation made in a previous study,\textsuperscript{21} 2 (Patients 4 and 10) of 3 patients (Patients 4, 6, and 10) in our series with unilateral disease seen on initial imaging progressed and developed contralateral MMS before EDAS/EMAS. With pre-EDAS/EMAS HbS levels of 26.9%, 23.0%, and 22.4%, respectively, their HbS levels were equally well controlled.

Historically, our institution has not recommended aspirin for stroke prevention in children with SCD and MMS because of bleeding concerns in a young adult population that has a known increased risk of hemorrhagic stroke.\textsuperscript{29} Although a recent single-center retrospective review suggested the safety and benefit of aspirin in this population,\textsuperscript{23} we feel that a prospective randomized trial is required before recommending aspirin for the prevention of stroke in children with SCD and MMS.

**Surgical Management of MMS in Patients With SCD**

EDAS was first reported in 1981\textsuperscript{24} as a surgical treatment for MMD in the Asian population and has become the preferred technique for indirect revascularization in patients with SCD. The technique requires the exposure and dissection of a branch of the superficial temporal artery, usually the parietal branch, with preservation of flow throughout the entirety of the procedure. Once the artery is isolated, it is mobilized, and a craniotomy overlying the sylvian fissure is performed. The arachnoid is opened extensively, and the superficial temporal artery branch is tagged to the pia of the cortical surface. Variations in the procedure have been reported and include EMAS, in which the donor artery is transposed with a small muscle cuff still attached. Other variations include encephalomyosynangiosis,\textsuperscript{22} the addition of bur holes,\textsuperscript{14,20} inversion of the dura,\textsuperscript{1} or a combination of the aforementioned procedures.\textsuperscript{22} Dural inversion is performed in hopes that the middle meningeal artery circulation that richly vascularizes the outer dural surface will serve as a source of collateral formation once brought into contact with the cortical surface.\textsuperscript{13} In our series, EMAS was performed on 7 hemispheres (Patients 1–6), and the remainder of the patients underwent EDAS with or without dural inversion. The complication rates for EMAS and EDAS were 28.6% (Patients 1 and 6) and 14.3% of hemispheres (Patients 7 and 14), respectively, with 1 transient neurological deficit in a child who suffered a stroke 2 weeks after EMAS.

All the patients in our series with radiological follow-up had a patent graft. Consistent with observations from other series, despite progressive intracranial vascular disease, the graft remained patent after EDAS/EMAS.\textsuperscript{12,13} Of the hemispheres on which surgery was performed, all but 1 (93.8%) showed radiological evidence of collateral formation at the last follow-up, which is consistent with the existing literature in which 87% of hemispheres on which surgery was performed demonstrated arterial ingrowth.\textsuperscript{21} Radiological follow-up was obtained routinely via MRA in the majority of cases to eliminate risks associated with DSA.

In the pediatric population, indirect revascularization has several advantages over direct revascularization (i.e., superficial temporal artery–to–MCA bypass). Direct bypass is technically challenging in the pediatric population because of the smaller diameter of the arteries and has been associated with symptomatic hyperperfusion, particularly in patients with MMS,\textsuperscript{19} and perioperative ischemic events during temporary artery occlusion, which is necessary when performing the anastomosis.\textsuperscript{21} The progression of vascular disease in patients with MMS may be accelerated with direct bypass.\textsuperscript{18} Compared with direct bypass, perioperative complications with EDAS/EMAS occur less frequently, because the procedure is less technically challenging, temporary artery occlusion is not required, and symptomatic hyperperfusion does not occur because it does not rely on a direct arterial anastomosis. The rate of nonneurological complications such as wound infections or pseudomeningocele was 11% in another series.\textsuperscript{21} No nonneurological complications occurred in our study.

**Stroke Prevention in Patients With SCD and MMS After EDAS**

Combining our experience with that in previously published series reports in which indirect revascularization for MMS and SCD was evaluated, a total of 69 EDAS/EMAS procedures were performed in 44 patients.\textsuperscript{21,12,34} Three-fourths of all patients combined had an ischemic stroke before EDAS/EMAS, and no patient presented with intracranial hemorrhage. Forty-seven percent of the patients had a stroke while on chronic transfusion therapy. In our study, there was 1 stroke per 7.8 patient-years during the pre-EDAS/EMAS follow-up period. After EDAS/EMAS, the rate dropped to 1 stroke per 39.3 patient-years, a 5-fold reduction of that in the pre-EDAS/EMAS period. These results are strikingly similar to the changes in stroke rates observed in all previous case series combined.\textsuperscript{21,32,34} There, the stroke rate dropped from 1 stroke per 13 patient-years before EDAS/EMAS to 1 stroke per 81 patient-years after EDAS/EMAS, a 6-fold decrease.\textsuperscript{21} This stroke reduction included 10 clinically silent ischemic events that occurred in 9 patients (64.3%) in the present study. Silent events are reported in 27.5% of patients with SCD and MMS on chronic transfusion therapy.\textsuperscript{19} Although these events do not necessarily manifest as clinically diagnosed strokes (i.e., hemiparesis, aphasia, etc.), they may be associated with progressive cognitive decline.

SCD is most prevalent in African Americans and Hispanics but can occur in people of all races. It is estimated that approximately 1 in 500 African American babies born in the United States has the disease.\textsuperscript{46} In the Nationwide Inpatient Sample database, there were 2,024 hospitalizations for stroke identified from 1993 to 2009, approximately 0.4% of all hospitalizations for pediatric patients with SCD. The mean annual incidence rate of hospitalization for stroke in pediatric patients with SCD during
the years 1999–2009 had decreased by 45% compared with the incidence from 1993 to 1998. Publication of the STOP results and the use of hydroxyurea are possible reasons for the decrease in stroke hospitalizations. Of the 62 patients currently on chronic transfusion therapy at our institution, 18.8% and 52.1% of the patients are treated for primary or secondary stroke prevention, respectively. Despite the relatively high prevalence of pediatric SCD and use of chronic transfusion therapy for stroke prevention, EDAS/EMAS seems to be performed relatively infrequently to prevent transfusion therapy for stroke prevention. EDAS/EMAS procedures in 44 patients have been reported in a highly selected group of patients with SCD. Of the 6 patients with MMS in our study who were on chronic transfusion therapy for secondary stroke prevention, 2 were offered EDAS/EMAS but declined. Compliance and adherence to chronic transfusion therapy is paramount for the selection of patients with MMS for EDAS/EMAS. Here, patients who did not undergo EDAS/EMAS were significantly less well controlled on chronic transfusion therapy, as evidenced by their higher HbS levels, which made them less favorable candidates for these procedures.

Limitations
The most important limitation of this and other studies lies in the potentially flawed study design. Like the study presented here, previous studies have used pre-EDAS/EMAS stroke rates and compared them to post-EDAS/EMAS stroke rates as their main end point. Although the magnitude of the drop in the post-EDAS/EMAS stroke rate was remarkable in our and other studies, no study has directly compared EDAS/EMAS to the best nonsurgical therapy. Given the long interval between first stroke and surgical revascularization in our study, the natural history of SCD with MMS may be less malignant than in classic MMD. It is our experience that, although most of these children have not had another clinically diagnosed stroke after their initial event, the majority of them have experienced significant cognitive decline, development of headache syndromes, and other behavioral disturbances. Whether these changes are a result of microvascular or macrovascular events (and thus are treatable by EDAS/EMAS) is unclear. The high rate of silent ischemic events (64% of patients) visualized on MRI in this series, however, may account for at least some of the cognitive decline. Future studies clearly need more subtle outcome measures, including but not limited to cognitive performance, patient symptom scores, and quantitative MRI/MRA to adequately substantiate the efficacy of EDAS/EMAS for improving the lives of children with SCD and MMS. Using these end points, a randomized prospective multicenter trial is needed to more definitively determine the efficacy of EDAS/EMAS as an adjunct to standard transfusion therapy in the management of children with this challenging disease.

Conclusions
The results of this study, consistent with those from other centers, suggest that indirect revascularization in pediatric patients with SCD and MMS is safe and may result in a significant reduction of stroke risk in these patients. However, drawing widespread conclusions from the study design is problematic given the unclear natural history of the disease, limitations of stroke as an outcome measure, and the lack of true randomized comparison with nonsurgical therapy only. Given these limitations and the relative rarity of children with SCD and MMS, a definitive, prospective, multicenter trial that evaluates the efficacy of EDAS/EMAS as an adjunct to transfusion therapy for preventing stroke and other cognitive sequelae is warranted.

Acknowledgment
We acknowledge Michael R. DeBaun, MD, MPH, Department of Pediatric Hematology Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt (Nashville, TN), for his assistance with this project.

References


Author Contributions

Correspondence
James M. Johnston, 1530 3rd Ave. S, Birmingham, AL 35209. email: james.johnston@childrensal.org.